Hadasit Bio-Holdings Ltd. is a forward-looking entity specializing in the Biopharma, Biotechnology, Health Care, and Pharmaceutical sectors. As a publicly traded subsidiary of the prestigious Hadassah University Hospital, it leverages its roots in Israel's leading medical research landscape to propel its proprietary initiatives.
Founded in 2005, Hadasit Bio-Holdings Ltd. is uniquely positioned at the intersection of clinical development and strategic business support. With a key focus on advancing portfolio companies towards Phase II clinical trials, it acts as a catalyst in facilitating pre-clinical trials, manufacturing, regulatory navigation, and business development processes.
The company's most recent $4.00M Series A investment on April 23, 2010, was spearheaded by noteworthy investors such as Pontifax, Clal Biotechnology Industries, and HBL Hadasit Bio Holdings. Despite its operational base in the United States, its global approach marks significant influence in sustaining cutting-edge medical breakthroughs.